Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
99% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. ATRS: No Debt )
ATRS' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.60
ATRS's Equity to Asset is ranked higher than
74% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. ATRS: 0.60 )
ATRS' s 10-Year Equity to Asset Range
Min: -4.09   Max: 0.94
Current: 0.6

-4.09
0.94
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
98% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.94 vs. ATRS: No Debt )
ATRS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 2.77
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -132.49
ATRS's Operating margin (%) is ranked lower than
52% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.43 vs. ATRS: -132.49 )
ATRS' s 10-Year Operating margin (%) Range
Min: -1709.11   Max: -26.96
Current: -132.49

-1709.11
-26.96
Net-margin (%) -132.64
ATRS's Net-margin (%) is ranked lower than
52% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. ATRS: -132.64 )
ATRS' s 10-Year Net-margin (%) Range
Min: -1728.74   Max: -26.66
Current: -132.64

-1728.74
-26.66
ROE (%) -62.42
ATRS's ROE (%) is ranked higher than
50% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. ATRS: -62.42 )
ATRS' s 10-Year ROE (%) Range
Min: -6822.87   Max: -19.42
Current: -62.42

-6822.87
-19.42
ROA (%) -43.61
ATRS's ROA (%) is ranked lower than
51% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. ATRS: -43.61 )
ATRS' s 10-Year ROA (%) Range
Min: -530.86   Max: -15.37
Current: -43.61

-530.86
-15.37
ROC (Joel Greenblatt) (%) -401.81
ATRS's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.59 vs. ATRS: -401.81 )
ATRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2300.72   Max: -394.95
Current: -401.81

-2300.72
-394.95
Revenue Growth (3Y)(%) 5.60
ATRS's Revenue Growth (3Y)(%) is ranked higher than
76% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ATRS: 5.60 )
ATRS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.4   Max: 89.8
Current: 5.6

-63.4
89.8
EBITDA Growth (3Y)(%) 86.60
ATRS's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ATRS: 86.60 )
ATRS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9   Max: 86.6
Current: 86.6

-41.9
86.6
EPS Growth (3Y)(%) 75.40
ATRS's EPS Growth (3Y)(%) is ranked higher than
97% of the 229 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. ATRS: 75.40 )
ATRS' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1   Max: 75.4
Current: 75.4

-58.1
75.4
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ATRS Guru Trades in Q1 2014

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q2 2014

ATRS Guru Trades in Q2 2014

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q3 2014

ATRS Guru Trades in Q3 2014

Jim Simons 145,728 sh (New)
Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q4 2014

ATRS Guru Trades in Q4 2014

Jean-Marie Eveillard 20,000 sh (unchged)
Jim Simons 85,970 sh (-41.01%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 30.21
ATRS's Forward P/E is ranked higher than
69% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.73 vs. ATRS: 30.21 )
N/A
P/B 8.90
ATRS's P/B is ranked lower than
55% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. ATRS: 8.90 )
ATRS' s 10-Year P/B Range
Min: 2.26   Max: 77.5
Current: 8.9

2.26
77.5
P/S 13.90
ATRS's P/S is ranked lower than
74% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.32 vs. ATRS: 13.90 )
ATRS' s 10-Year P/S Range
Min: 3.56   Max: 36
Current: 13.9

3.56
36
EV-to-EBIT -9.06
ATRS's EV-to-EBIT is ranked higher than
61% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.87 vs. ATRS: -9.06 )
ATRS' s 10-Year EV-to-EBIT Range
Min: -121.9   Max: -1
Current: -9.06

-121.9
-1
Current Ratio 2.21
ATRS's Current Ratio is ranked higher than
67% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. ATRS: 2.21 )
ATRS' s 10-Year Current Ratio Range
Min: 0.21   Max: 14.51
Current: 2.21

0.21
14.51
Quick Ratio 1.97
ATRS's Quick Ratio is ranked higher than
76% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. ATRS: 1.97 )
ATRS' s 10-Year Quick Ratio Range
Min: 0.21   Max: 14.09
Current: 1.97

0.21
14.09
Days Inventory 232.28
ATRS's Days Inventory is ranked higher than
57% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 133.28 vs. ATRS: 232.28 )
ATRS' s 10-Year Days Inventory Range
Min: 11.13   Max: 200.11
Current: 232.28

11.13
200.11
Days Sales Outstanding 48.34
ATRS's Days Sales Outstanding is ranked higher than
88% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.74 vs. ATRS: 48.34 )
ATRS' s 10-Year Days Sales Outstanding Range
Min: 15.98   Max: 266.58
Current: 48.34

15.98
266.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 30.23
ATRS's Price/Net Cash is ranked higher than
86% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ATRS: 30.23 )
ATRS' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 85
Current: 30.23

2.06
85
Price/Net Current Asset Value 13.60
ATRS's Price/Net Current Asset Value is ranked higher than
79% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ATRS: 13.60 )
ATRS' s 10-Year Price/Net Current Asset Value Range
Min: 1.8   Max: 34
Current: 13.6

1.8
34
Price/Tangible Book 9.71
ATRS's Price/Tangible Book is ranked higher than
58% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.30 vs. ATRS: 9.71 )
ATRS' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 44.5
Current: 9.71

0.62
44.5
Price/Median PS Value 1.04
ATRS's Price/Median PS Value is ranked higher than
84% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. ATRS: 1.04 )
ATRS' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.35
Current: 1.04

0.08
2.35
Earnings Yield (Greenblatt) -10.80
ATRS's Earnings Yield (Greenblatt) is ranked lower than
51% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. ATRS: -10.80 )
ATRS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.8   Max: 0
Current: -10.8

-11.8
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MJC.Germany,
Antares Pharma Inc was incorporated on February 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 


More From Other Websites
ANTARES PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 27 2015
Antares Pharma Regains US Marketing Rights to Otrexup for Psoriasis Indication Apr 27 2015
7:04 am Antares Pharma regains U.S. marketing rights to OTREXUP for psoriasis indication and... Apr 27 2015
Antares Pharma Regains U.S. Marketing Rights to OTREXUP for Psoriasis Indication - Announces... Apr 27 2015
Antares Pharma (ATRS) Enters Overbought Territory - Tale of the Tape Apr 16 2015
Antares Pharma Announces Settlement of Patent Infringement Lawsuits Apr 16 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 16 2015
Antares Pharma Announces Settlement of Patent Infringement Lawsuits Apr 16 2015
Initiating Coverage on the Most Compelling Drug Reformulation Story of 2015 Apr 09 2015
Antares Pharma Announces FDA Approval of TEVTROPIN 10 mg Human Growth Hormone NeedleFree Injector Mar 31 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 31 2015
Antares Pharma Announces FDA Approval of TEV-TROPIN(R) 10 mg (Human Growth Hormone) Needle-Free... Mar 31 2015
ANTARES PHARMA, INC. Financials Mar 18 2015
Antares Pharma reports 4Q loss Mar 12 2015
Antares Pharma reports 4Q loss Mar 12 2015
Antares Pharma Reports Fourth Quarter and Full Year 2014 Operating and Financial Results Mar 12 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 12 2015
Q4 2014 Antares Pharma Inc Earnings Release - Before Market Open Mar 12 2015
Antares Pharma Reports Fourth Quarter and Full Year 2014 Operating and Financial Results Mar 12 2015
Antares Pharma To Host Fourth Quarter 2014 Operating and Financial Results Call Mar 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK